Format

Send to

Choose Destination
See comment in PubMed Commons below
Cell Metab. 2012 Jan 4;15(1):19-24. doi: 10.1016/j.cmet.2011.10.012.

Metabolic disease drug discovery- "hitting the target" is easier said than done.

Author information

1
Division of Endocrinology and Cardiovascular Discovery Research and Clinical Investigation, Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN 46285, USA. mollerda@lilly.com

Abstract

Despite the advent of new drug classes, the global epidemic of cardiometabolic disease has not abated. Continuing unmet medical needs remain a major driver for new research. Drug discovery approaches in this field have mirrored industry trends, leading to a recent increase in the number of molecules entering development. However, worrisome trends and newer hurdles are also apparent. The history of two newer drug classes-glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors-illustrates both progress and challenges. Future success requires that researchers learn from these experiences and continue to explore and apply new technology platforms and research paradigms.

PMID:
22225873
DOI:
10.1016/j.cmet.2011.10.012
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center